Bladder and kidney tumors are the two most common tumors in the urinary tract, and the incidence is increasing year by year, which seriously threatens human health. The team of urology experts led by Professor Zheng Junhua from Department of Urology, Shanghai Tenth People’s Hospital of Tongji University has conducted more than ten years of research on many difficult problems faced in the diagnosis and treatment of kidney and bladder cancers from basic to clinical, and has systematically and comprehensively studied the biological behaviors of kidney and bladder cancers, such as occurrence, development, infiltration and metastasis, as well as personalized treatment strategies such as minimally invasive treatment and alternative treatment. He has conducted in-depth research on the biological behaviors of kidney and bladder cancers, including the occurrence, development, infiltration and metastasis, as well as personalized treatment strategies such as minimally invasive treatment and alternative therapy. Recently, his research result, “Biological Behavior of Urological Tumors and Individualized Treatment Strategies”, won the first prize of Science and Technology Progress Award of the Ministry of Education. This is the highest award in the field of science and technology innovation of the Ministry of Education. As one of the most important researches on kidney cancer and bladder cancer in recent years, it is expected to create a “new world” in the diagnosis and treatment of kidney cancer, bladder cancer and other urological tumors. In the journey of conquering malignant tumors, medical scientists are constantly making new discoveries. The brand-new discovery of Zheng Junhua’s research team is that it is the first to discover that kidney and bladder cancers, as uroepithelial tumors and uroepithelial tumors, have obvious similarities in their occurrence, development and metastasis, thus revealing the intrinsic rules of tumor progression of the two major tumors. The series of studies revealed the intrinsic relationship between multiple oncogenes and biological behaviors of kidney and bladder tumors, further uncovered the mechanism of multiple genes and coordinated effects of biological behaviors of kidney and bladder cancers, and based on this, explored targeted therapies for kidney and bladder cancers, thus effectively reducing the recurrence and metastasis rates of bladder tumors and improving the tumor-free survival rate and long-term survival quality of patients. This research result is a milestone in explaining the occurrence and development of kidney and bladder tumors and improving the treatment effect of tumors in different periods. The team led by Prof. Zheng took the lead in conducting research on multicenter lesions of kidney cancer at home and abroad, systematically solved the problems and confusions of minimally invasive laparoscopic treatment of kidney cancer, and proposed the “China-Tongji standard for kidney-preserving surgery” for the first time in the world, that is, in the operation of preserving kidney units in early stage kidney cancer, the extent of parenchymal resection should be far away from the kidney unit. These research results were widely accepted by urologists from all over the world and have preserved the kidney function of numerous patients to the greatest extent. At the same time, the Department of Urology of the Tenth Hospital has taken the lead in conducting evidence-based medical research on personalized strategy treatment of kidney cancer with large samples and multiple centers in China, and has formulated new strategies for individualized and minimally invasive treatment of early-stage kidney cancer, forming two characteristics of “high kidney preservation” and “high minimally invasive”; it has carried out He has carried out single-port laparoscopic surgery and laparoscopic and CT-guided radiofrequency ablation for small kidney cancer; continuously improved techniques and instruments, and established a new system of comprehensive treatment for middle and late stage kidney and bladder cancer, achieving the goals of “high resection” and “high survival”. During the past ten years, the team led by Prof. Zheng Junhua has completed more than 2,500 surgical treatments for kidney and bladder tumors, all of which have achieved significant results; the survival time of patients with advanced kidney and bladder tumors has increased by 6 months to 2 years, further improving the level of diagnosis and treatment of kidney and bladder tumors. Currently, the 5-year overall survival rate of patients with intermediate and advanced kidney cancer has reached 80.9%, while the overall survival rate of bladder cancer has reached 58.5%.